NasoShield (anthrax intranasal vaccine) / Altimmune - LARVOL DELTA

NasoShield Study of Safety and Immunogenicity (clinicaltrials.gov) - P1 | N=145 | Completed | Sponsor: Altimmune, Inc. | Unknown status ➔ Completed

Trial completion

NasoShield in Healthy Adults to Study Safety and Immunogenicity (clinicaltrials.gov) - P1; N=42; Completed; Sponsor: Altimmune, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

NasoShield in Healthy Adults to Study Safety and Immunogenicity (clinicaltrials.gov) - P1; N=42; Active, not recruiting; Sponsor: Altimmune, Inc.; Trial primary completion date: Nov 2020 ➔ Mar 2021

Clinical • Trial primary completion date

NasoShield in Healthy Adults to Study Safety and Immunogenicity (clinicaltrials.gov) - P1; N=42; Active, not recruiting; Sponsor: Altimmune, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

NasoShield in Healthy Adults to Study Safety and Immunogenicity (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Altimmune, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

NasoShield in Healthy Adults to Study Safety and Immunogenicity (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Altimmune, Inc.

Clinical • New P1 trial